Carfilzomib Patent Expiration
Carfilzomib is Used for treating relapsed or refractory multiple myeloma in patients who have received one to three lines of therapy. It was first introduced by Onyx Pharmaceuticals Inc A Wholly Owned Sub Of Amgen Inc
Carfilzomib Patents
Given below is the list of patents protecting Carfilzomib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Kyprolis | US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | Feb 27, 2033 | Onyx Pharms Amgen |
| Kyprolis | US9511109 | Combination therapy with peptide epoxyketones | Oct 21, 2029 | Onyx Pharms Amgen |
| Kyprolis | USRE47954 | Combination therapy with peptide epoxyketones | Oct 21, 2029 | Onyx Pharms Amgen |
| Kyprolis | US7737112 | Composition for enzyme inhibition | Dec 07, 2027 | Onyx Pharms Amgen |
| Kyprolis | US7417042 | Compounds for enzyme inhibition | Jul 20, 2026 | Onyx Pharms Amgen |
| Kyprolis | US7232818 | Compounds for enzyme inhibition | Apr 14, 2025 | Onyx Pharms Amgen |
| Kyprolis | US7491704 | Compounds for enzyme inhibition | Apr 14, 2025 | Onyx Pharms Amgen |
| Kyprolis | US8129346 | Compounds for enzyme inhibition | Apr 14, 2025 | Onyx Pharms Amgen |
| Kyprolis | US8207125 | Compounds for enzyme inhibition | Apr 14, 2025 | Onyx Pharms Amgen |
| Kyprolis | US8207126 | Compounds for enzyme inhibition | Apr 14, 2025 | Onyx Pharms Amgen |
| Kyprolis | US8207127 | Compounds for enzyme inhibition | Apr 14, 2025 | Onyx Pharms Amgen |
| Kyprolis | US8207297 | Compounds for enzyme inhibition | Apr 14, 2025 | Onyx Pharms Amgen |
Carfilzomib's Family Patents
Explore Our Curated Drug Screens
Carfilzomib Generic API Manufacturers
Several generic applications have been filed for Carfilzomib. The first generic version for Carfilzomib was by Dr Reddys Laboratories Ltd and was approved on Sep 9, 2019. And the latest generic version is by Breckenridge Pharmaceutical Inc and was approved on Jun 11, 2021.
Given below is the list of companies who have filed for Carfilzomib generic, along with the locations of their manufacturing plants worldwide.
1. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Carfilzomib. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Mar 16, 2020 |
| 30MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Mar 20, 2020 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
2. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 2 different strengths of generic version for Carfilzomib. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Jun 11, 2021 |
| 10MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Jun 11, 2021 |
Manufacturing Plant Locations New
Breckenridge's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Breckenridge as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
3. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Carfilzomib. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG/VIAL | powder | Prescription | INTRAVENOUS | AP | Sep 9, 2019 |